InflaRx N.V. — FY2019 Form 20-F
Reporting period: Fiscal year ended December 31, 2019; this is an audited annual report, not a standalone fourth-quarter report. InflaRx is a clinical-stage biopharmaceutical company developing anti-C5a therapies, principally IFX-1. Financial statements are prepared under IFRS in euros. The company reported no product revenue.
Key financial metrics
| Metric | FY2019 | FY2018 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | €44.6 million | €25.0 million |
| General and administrative expense | €12.5 million | €12.8 million |
| Operating loss | €56.8 million | €37.5 million |
| Net loss | €53.3 million | €29.8 million |
| Basic and diluted loss per share | €2.05 | €1.19 |
| Net cash used in operating activities | €43.2 million | €21.5 million |
| Cash and cash equivalents at year-end | €33.1 million | €55.4 million |
| Marketable securities at year-end | €81.9 million | €100.9 million |
| Total assets / total liabilities | €121.6 million / €14.4 million | €159.2 million / €7.8 million |
| Total equity | €107.1 million | €151.4 million |
R&D and G&A totaled €57.1 million in 2019. No operating or profit margins are meaningful because the company had no product sales and incurred losses. Net financial income was €3.5 million, including foreign-exchange gains and interest income; it partly offset the operating loss. The company reported no financial debt apart from lease liabilities (about €0.85 million at year-end) and trade and other payables. Total funds available, including cash and financial assets, were reported as €115.8 million in the financial-statement notes. Contractual CRO and other service commitments totaled €24.4 million; total contractual obligations, including leases, were €25.4 million.
Material changes versus FY2018
- Net loss increased by €23.4 million, about 79%, primarily as R&D spending rose €19.6 million. Third-party R&D costs increased €20.9 million, largely for IFX-1 trials and clinical-material manufacturing.
- Operating cash use rose to €43.2 million from €21.5 million. Cash and cash equivalents fell €22.3 million; marketable securities also declined as investments matured and were reinvested or used to support operations.
- Net financial income fell €4.2 million, mainly because foreign-exchange gains were lower than in 2018. Currency movements on U.S.-dollar assets materially affect reported results; the company had no currency hedges.
- Share-based compensation expense was €6.8 million, down from €12.1 million. In July 2019, the company repriced many employee and director options to $3.35 per share, creating incremental compensation expense.
Business, outlook, risks and unusual items
- HS: The 179-patient Phase IIb SHINE trial did not meet its primary endpoint: no statistically significant dose-response in HiSCR at week 16. Reported HiSCR rates were 40.0% for placebo and 38.7%–51.5% across active dose groups. Management highlighted post-hoc analyses suggesting improvements in lesions and draining fistulas, and extension-study results; these are not substitutes for the failed primary endpoint and were not pre-specified. The company sought an FDA end-of-Phase-II meeting to discuss possible further development and an alternative endpoint.
- Other pipeline: The AAV Phase II program was streamlined after blinded interim analyses and consideration of COVID-19 impacts: the U.S. IXPLORE study was to stop early and be read out; the European IXCHANGE study was to continue with a smaller Part 2. In an exploratory PG study, two of the first five patients had complete closure of the target ulcer; this is preliminary, small-sample evidence. The company planned a Phase II oncology study and, in March 2020, began a 30-patient IFX-1 study in severe COVID-19 pneumonia. These are developments reported after the 2019 year-end.
- Funding and guidance: Management expected operating expenses to decrease in 2020 and rise again in later years as development advances. A potential HS Phase III program was estimated to cost €60–€80 million. The filing says cash, cash equivalents and marketable securities were expected to fund the current business plan for at least 24 months, but another financial-statement note describes funding for at least 12 months from December 31, 2019. No committed external funding source was disclosed; additional capital may be needed and could dilute shareholders or require partnering or licensing.
- COVID-19 and supply: Management warned of potential disruption to trials, recruitment, CRO operations and financing from the pandemic. IFX-1 clinical supply depended on a sole manufacturer in China; the company said no supply-chain impact had yet occurred but could not assure continuity.
- Other risks and contingencies: The company has never generated product revenue, has an accumulated deficit of €134.4 million, and expects continued losses. IFX-1’s HS efficacy and regulatory path remain uncertain; recruitment in AAV and PG had been slower than expected. Foreign-exchange exposure, competition, manufacturing scale-up, reimbursement, intellectual-property protection and potential financing needs are material risks. The company believed it was likely a PFIC for U.S. tax purposes in 2018 and 2019. It reported no material litigation and no off-balance-sheet arrangements other than operating leases and cancellable/contractual service arrangements.
- Audit and controls: KPMG issued an unqualified audit opinion on the IFRS financial statements. Management concluded disclosure controls and internal control over financial reporting were effective at year-end; the auditor did not attest to internal-control effectiveness.
Most important facts for investors to verify
- Reconcile the stated 12-month and 24-month liquidity/runway disclosures, and test whether projected spending, contractual commitments and the potential €60–€80 million HS Phase III cost are funded.
- Review the full SHINE data and any FDA/EMA feedback on whether IFX-1 can proceed in HS, including the acceptability of an alternative primary endpoint and the evidentiary weight of post-hoc and extension results.
- Track readouts and enrollment changes in AAV and PG, and validate whether preliminary PG results and planned oncology/COVID-19 studies translate into reproducible clinical benefit.
- Assess continued reliance on the single China-based IFX-1 manufacturer and the pandemic’s effect on supply, trial execution and recruitment.
- Monitor cash burn, financing plans and dilution risk, as well as U.S.-dollar/euro exposure and potential PFIC tax consequences for U.S. shareholders.